ContraFect (CFRX) Announces Quarterly Earnings Results

ContraFect (NASDAQ:CFRX) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.04, MarketWatch Earnings reports.

NASDAQ CFRX traded down $0.19 on Friday, hitting $2.19. 153,100 shares of the company’s stock traded hands, compared to its average volume of 170,664. ContraFect has a 1-year low of $0.85 and a 1-year high of $2.93. The stock has a market cap of $189.79 million, a price-to-earnings ratio of -5.92 and a beta of -0.37.

Separately, ValuEngine upgraded shares of ContraFect from a “hold” rating to a “buy” rating in a research note on Tuesday.

WARNING: This article was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2018/11/09/contrafect-cfrx-announces-quarterly-earnings-results.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

See Also: Growth Stocks, What They Are, What They Are Not

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply